Comparative Pharmacology
Head-to-head clinical analysis: ICLUSIG versus PONATINIB HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICLUSIG versus PONATINIB HYDROCHLORIDE.
ICLUSIG vs PONATINIB HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.
45 mg orally once daily with or without food.
45 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing.
Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose.
Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor